T1	Condition 29 62	central nervous system metastases
T2	Qualifier 76 83	another
T3	Condition 84 94	malignancy
T4	Condition 103 113	Malignancy
T5	Procedure 114 142	treated with curative intent
T6	Negation 152 154	no
T7	Condition 161 175	active disease
R1	Has_negation Arg1:T7 Arg2:T6	
T8	Temporal 184 216	for >=5 years prior to enrolment
T9	Reference_point 207 216	enrolment
R2	Has_index Arg1:T8 Arg2:T9	
T10	Mood 221 243	felt to be at low risk
T11	Condition 248 258	recurrence
R3	Has_mood Arg1:T11 Arg2:T10	
T12	Qualifier 286 296	Adequately
T13	Condition 305 333	non-melanomatous skin cancer
T14	Procedure 297 304	treated
R4	Has_qualifier Arg1:T14 Arg2:T12	
T15	Condition 337 352	lentigo maligna
*	OR T13 T15
T16	Condition 361 380	evidence of disease
T17	Negation 353 360	without
R5	Has_negation Arg1:T16 Arg2:T17	
T18	Qualifier 382 392	Adequately
T19	Procedure 393 400	treated
R6	Has_qualifier Arg1:T19 Arg2:T18	
T20	Condition 401 427	cervical carcinoma in situ
T21	Negation 428 435	without
T22	Condition 448 455	disease
R7	Has_negation Arg1:T22 Arg2:T21	
T23	Scope 305 352	non-melanomatous skin cancer or lentigo maligna
R8	AND Arg1:T23 Arg2:T14	
R9	AND Arg1:T23 Arg2:T16	
R10	AND Arg1:T20 Arg2:T19	
R11	AND Arg1:T20 Arg2:T22	
T24	Condition 457 492	Prostatic intraepithelial neoplasia
T25	Condition 513 528	prostate cancer
T26	Negation 493 500	without
T27	Mood 436 447	evidence of
R12	Has_mood Arg1:T22 Arg2:T27	
T28	Mood 501 512	evidence of
R13	Has_mood Arg1:T25 Arg2:T28	
R14	Has_negation Arg1:T25 Arg2:T26	
R15	AND Arg1:T24 Arg2:T25	
*	OR T20 T24 T23
R16	AND Arg1:T4 Arg2:T5	
R17	AND Arg1:T4 Arg2:T7	
R18	Has_temporal Arg1:T7 Arg2:T8	
*	OR T4 T14
R19	Has_qualifier Arg1:T3 Arg2:T2	
T29	Negation 95 101	except
T30	Scope 103 528	Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer
R20	Has_negation Arg1:T30 Arg2:T29	
R21	Has_scope Arg1:T3 Arg2:T30	
T31	Condition 550 583	delayed hypersensitivity reaction
T32	Condition 537 546;558 583	immediate hypersensitivity reaction
*	OR T31 T32 T36
T33	Condition 587 599	idiosyncrasy
T34	Drug 603 642	drugs chemically related to panitumumab
T35	Drug 603 642;646 656	drugs chemically related to panitumumab excipients
*	OR T34 T35
T36	Scope 603 656	drugs chemically related to panitumumab or excipients
R22	AND Arg1:T36 Arg2:T33	
T37	Procedure 706 743;751 767	anti-epidermal growth factor receptor antibody therapy
T38	Drug 775 786	panitumumab
T39	Drug 790 799	cetuximab
*	OR T39 T38
T40	Scope 775 799	panitumumab or cetuximab
R23	Subsumes Arg1:T37 Arg2:T40	
T41	Procedure 745 749	EGFr
R24	Subsumes Arg1:T37 Arg2:T41	
T42	Procedure 804 849	treatment with small molecule EGFr inhibitors
T43	Drug 857 866	gefitinib
T44	Drug 868 877	erlotinib
T45	Drug 879 888	lapatinib
*	OR T45 T44 T43
T46	Scope 857 888	gefitinib, erlotinib, lapatinib
R25	Subsumes Arg1:T42 Arg2:T46	
*	OR T42 T37
T47	Procedure 892 909	Antitumor therapy
T48	Procedure 917 929	chemotherapy
T49	Procedure 931 947	hormonal therapy
T50	Procedure 949 962	immunotherapy
T51	Procedure 964 980	antibody therapy
T52	Procedure 982 994	radiotherapy
*	OR T52 T51 T50 T49 T48
T53	Scope 917 994	chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy
R26	Subsumes Arg1:T47 Arg2:T53	
T54	Drug 1000 1021	investigational agent
T55	Procedure 1025 1032	therapy
T56	Temporal 1033 1079	<=30 days before first dose of study treatment
T57	Condition 1083 1120	not recovered from any acute toxicity
T58	Reference_point 1050 1079	first dose of study treatment
R27	Has_index Arg1:T56 Arg2:T58	
*	OR T54 T55 T47
T59	Scope 892 1032	Antitumor therapy (e.g., chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy
R28	Has_temporal Arg1:T59 Arg2:T56	
*	OR T59 T57
T60	Temporal 1155 1183	<=30 days before study entry
T61	Qualifier 1123 1128	Other
T62	Procedure 1129 1154	investigational procedure
R29	Has_qualifier Arg1:T62 Arg2:T61	
R30	Has_temporal Arg1:T62 Arg2:T60	
T63	Condition 1197 1222	interstitial lung disease
T64	Condition 1224 1227	ILD
R31	Subsumes Arg1:T63 Arg2:T64	
T65	Condition 1235 1259	interstitial pneumonitis
T66	Condition 1261 1279	pulmonary fibrosis
T67	Mood 1283 1294	evidence of
T68	Condition 1295 1298	ILD
T69	Temporal 1302 1310	baseline
T70	Procedure 1311 1336	chest computer tomography
R32	Has_temporal Arg1:T70 Arg2:T69	
R33	Has_mood Arg1:T68 Arg2:T67	
R34	AND Arg1:T70 Arg2:T68	
*	OR T66 T70 T65
T71	Scope 1235 1336	interstitial pneumonitis, pulmonary fibrosis or evidence of ILD on baseline chest computer tomography
T72	Scope 1197 1228	interstitial lung disease (ILD)
R35	Subsumes Arg1:T72 Arg2:T71	
T73	Non-query-able 1339 1381	Subject previously enrolled to this study.
T74	Condition 1394 1403	keratitis
T75	Condition 1405 1425	ulcerative keratitis
T76	Qualifier 1429 1435	severe
T77	Condition 1436 1443	dry eye
R36	Has_qualifier Arg1:T77 Arg2:T76	
*	OR T77 T75 T74
T78	Procedure 1446 1459	Major surgery
T79	Procedure 1477 1495	general anesthesia
T80	Temporal 1497 1543	<=30 days before first dose of study treatment
T81	Reference_point 1514 1543	first dose of study treatment
R37	Has_index Arg1:T80 Arg2:T81	
R38	AND Arg1:T78 Arg2:T79	
R39	Has_temporal Arg1:T78 Arg2:T80	
T82	Non-query-able 1545 1610	Subjects must have recovered from any surgery related toxicities.
T83	Procedure 1612 1636	Minor surgical procedure
T84	Procedure 1644 1655	open biopsy
R40	Subsumes Arg1:T83 Arg2:T84	
T85	Temporal 1657 1702	<=7 days before first dose of study treatment
T86	Reference_point 1673 1702	first dose of study treatment
R41	Has_index Arg1:T85 Arg2:T86	
R42	Has_temporal Arg1:T83 Arg2:T85	
T87	Negation 1707 1714	not yet
T88	Condition 1715 1724	recovered
T89	Temporal 1730 1735	prior
T90	Procedure 1736 1749	minor surgery
R43	Has_temporal Arg1:T90 Arg2:T89	
R44	Has_negation Arg1:T88 Arg2:T87	
R45	AND Arg1:T88 Arg2:T90	
*	OR T83 T88
T91	Qualifier 1927 1949	Clinically significant
T92	Condition 1950 1972	cardiovascular disease
T93	Condition 1984 2005	myocardial infarction
T94	Condition 2007 2022	unstable angina
T95	Condition 2036 2060	congestive heart failure
T96	Qualifier 2024 2035	symptomatic
R46	Has_qualifier Arg1:T95 Arg2:T96	
T97	Qualifier 2062 2069	serious
T98	Qualifier 2070 2082	uncontrolled
T99	Condition 2083 2101	cardiac arrhythmia
R47	Has_qualifier Arg1:T99 Arg2:T98	
R48	Has_qualifier Arg1:T99 Arg2:T97	
T100	Temporal 2103 2132	<=6 months prior to enrolment
T101	Reference_point 2123 2132	enrolment
R49	Has_index Arg1:T100 Arg2:T101	
*	OR T93 T94 T95 T99
T102	Scope 1984 2101	myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia
*	OR T92 T91
T103	Scope 1927 1972	Clinically significant cardiovascular disease
R50	Subsumes Arg1:T103 Arg2:T102	
R51	Has_temporal Arg1:T103 Arg2:T100	
T104	Post-eligibility 2135 2447	History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with the study participation or investigational product administration, compliance with the study procedures or may interfere with the interpretation of the results.
T105	Qualifier 2449 2457	Unstable
T106	Condition 2458 2476	pulmonary embolism
R52	Has_qualifier Arg1:T106 Arg2:T105	
T107	Condition 2478 2498	deep vein thrombosis
T108	Qualifier 2503 2508	other
T109	Qualifier 2509 2520	significant
T110	Condition 2521 2529;2537 2557	arterial thromboembolic event
T111	Condition 2530 2557	venous thromboembolic event
T112	Temporal 2558 2604	<=30 days before first dose of study treatment
T113	Reference_point 2575 2604	first dose of study treatment
R53	Has_index Arg1:T112 Arg2:T113	
*	OR T110 T111
T114	Scope 2521 2557	arterial/venous thromboembolic event
R54	Has_qualifier Arg1:T114 Arg2:T109	
R55	Has_qualifier Arg1:T114 Arg2:T108	
*	OR T106 T107 T114
T115	Scope 2449 2557	Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event
R56	Has_temporal Arg1:T115 Arg2:T112	
T116	Procedure 2612 2627	anticoagulation
A1	Optional T116
T117	Qualifier 2648 2654	stable
T118	Multiplier 2655 2671	therapeutic dose
R57	Has_qualifier Arg1:T118 Arg2:T117	
T119	Temporal 2672 2710	prior to first dose of study treatment
T120	Reference_point 2681 2710	first dose of study treatment
*	OR T119 T120
R58	Has_multiplier Arg1:T116 Arg2:T118	
R59	Has_temporal Arg1:T116 Arg2:T119	
T121	Condition 2728 2736	pregnant
T122	Observation 2740 2754	breast feeding
T123	Observation 2771 2786	become pregnant
T124	Temporal 2787 2803	during treatment
T125	Temporal 2808 2868	within 2 months after the discontinuation of study treatment
T126	Reference_point 2830 2868	the discontinuation of study treatment
R60	Has_index Arg1:T125 Arg2:T126	
T127	Reference_point 2794 2803	treatment
R61	Has_index Arg1:T124 Arg2:T127	
T128	Scope 2787 2868	during treatment and within 2 months after the discontinuation of study treatment
*	OR T123 T122 T121
T129	Scope 2728 2786	pregnant or breast feeding, or planning to become pregnant
R62	Has_scope Arg1:T129 Arg2:T128	
T130	Measurement 2886 2936	test(s) for human immunodeficiency virus infection
T131	Value 2877 2885	positive
R63	Has_value Arg1:T130 Arg2:T131	
T132	Condition 3009 3018	infection
T133	Temporal 3002 3008	Active
R64	Has_temporal Arg1:T132 Arg2:T133	
T134	Procedure 3029 3047	systemic treatment
T135	Condition 3055 3077	uncontrolled infection
T136	Temporal 3078 3126	<=14 days prior to first dose of study treatment
T137	Reference_point 3097 3126	first dose of study treatment
R65	Has_index Arg1:T136 Arg2:T137	
R66	AND Arg1:T132 Arg2:T134	
*	OR T132 T135
T138	Qualifier 3051 3054	any
R67	Has_qualifier Arg1:T135 Arg2:T138	
T139	Scope 3002 3077	Active infection requiring systemic treatment or any uncontrolled infection
R68	Has_temporal Arg1:T139 Arg2:T136	
T140	Condition 3164 3187	urinary tract infection
T141	Qualifier 3150 3163	uncomplicated
R69	Has_qualifier Arg1:T140 Arg2:T141	
T142	Negation 3128 3149	with the exception of
T143	Condition 3191 3224	upper respiratory tract infection
R70	Has_qualifier Arg1:T143 Arg2:T141	
*	OR T140 T143
T144	Scope 3150 3224	uncomplicated urinary tract infection or upper respiratory tract infection
R71	Has_negation Arg1:T144 Arg2:T142	
R72	Has_scope Arg1:T139 Arg2:T144	
T145	Post-eligibility 3228 3437	Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures or is unwilling or unable to comply with study requirements.
T146	Mood 2759 2770	planning to
R73	Has_mood Arg1:T123 Arg2:T146	
